Skip to content
lifestyle.small-bizsense.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Jaguar Health, Inc.
Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer (FDA Approved Canalevia-CA1) for Treatment of Chemotherapy-Induced Diarrhea in Dogs
April 29, 2026
Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq’s Bid Price Rule; Company Announces Reverse Stock Split
April 27, 2026
Jaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN)
April 24, 2026
Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of Stockholders
April 20, 2026
←
Previous Page
1
2
3
4